Bezuclastinib (PLX 9486; CGT9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001<IC50<1 μM; extracted from patent WO2014100620 A2, compound P-2007). Bezuclastinib is a tyrosine kinase inhibitor.
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological Activity
Bezuclastinib (PLX 9486; CGT9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001<IC50<1 μM; extracted from patent WO2014100620 A2, compound P-2007). Bezuclastinib is a tyrosine kinase inhibitor.
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/Lin vitro: MGCD516 is superior to other multi-kinase inhibitors in inhibiting cell…
Elenestinib (BLU-263) is a potent and orally active tyrosine kinase inhibitor. Elenestinib has the potential for the research of systemic mastocytosis (SM).
Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
WZ4002 is a mutant selective EGFR inhibitor with IC50s of 2, 8, 3 and 2 nM for EGFRL858R, EGFRL858R/T790M, EGFRE746_A750 and EGFRE746_A750/T790M, respectively.
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
